Skip to main content
. 2017 Sep 27;8:707. doi: 10.1038/s41467-017-00786-z

Fig. 2.

Fig. 2

Transgenic expression of human IL-2 enables NOG mice to support viability of TILs. a Changes in IL-2 plasma levels in NOG mice injected with 45,000 U IL-2 over time and steady-state levels of IL-2 in hIL2-NOG mice. b In vivo bioluminescence images over time of two hIL2-NOG transgenic mice with different serum levels of hIL-2 injected with MM33 TILs labeled with a luciferase lentivirus. c Quantification of radiance of luciferase-expressing MM33 TILs growing in mice (from b) with different serum levels of IL-2. d In vivo bioluminescence images from different angles of tumor-bearing or non-tumor-bearing hIL2-NOG transgenic mice injected with luciferase-expressing MM33 TILs. The experiments shown here were performed once